TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Perseus Proteomics, Inc. ( (JP:4882) ) has shared an announcement.
Perseus Proteomics, Inc. has announced an extension of the Phase I/II clinical trial period for its anti-transferrin receptor 1 antibody, PPMX-T003, targeting aggressive NK-cell leukemia, due to difficulties in patient enrollment. The trial will now continue until March 31, 2027, with the potential impact on the company’s business performance still under review.
More about Perseus Proteomics, Inc.
Perseus Proteomics, Inc. operates in the biotechnology industry, focusing on the development of therapeutic antibodies. The company is engaged in creating innovative treatments for rare and challenging diseases, with a particular emphasis on aggressive NK-cell leukemia.
Average Trading Volume: 308,386
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.59B
For a thorough assessment of 4882 stock, go to TipRanks’ Stock Analysis page.